EA200601982A1 - Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов - Google Patents

Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов

Info

Publication number
EA200601982A1
EA200601982A1 EA200601982A EA200601982A EA200601982A1 EA 200601982 A1 EA200601982 A1 EA 200601982A1 EA 200601982 A EA200601982 A EA 200601982A EA 200601982 A EA200601982 A EA 200601982A EA 200601982 A1 EA200601982 A1 EA 200601982A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorder
disorders
sexual dysfunction
sex
selective
Prior art date
Application number
EA200601982A
Other languages
English (en)
Inventor
Шарлотта Мойра Норфор Аллертон
Эндрю Саймон Кук
Дейвид Хепуорт
Дункан Чарльз Миллер
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200601982A1 publication Critical patent/EA200601982A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

В настоящем изобретении предложены соединения формулы (I), которые представляют собой класс агонистов дофамина, более конкретно, класс агонистов, которые являются более селективными в отношении D3 по сравнению с D2. Эти соединения являются полезными для лечения и/или предотвращения сексуальной дисфункции, например женской сексуальной дисфункции (FSD), в частности расстройства женского полового возбуждения (FSAD), гипоактивного расстройства полового влечения (HSDD; отсутствие интереса к сексу), женского оргазмического расстройства (FOD; неспособность достижения оргазма); и мужской сексуальной дисфункции, в частности мужской эректильной дисфункции (MED). Мужская сексуальная дисфункция при упоминании здесь означает, что она включает эякуляторные расстройства, такие как преждевременная эякуляция, аноргазмия (неспособность достижения оргазма) или расстройства влечения, такие как гипоактивное расстройство полового влечения (HSDD; отсутствие интереса к сексу). Эти соединения также являются полезными в лечении нейропсихиатрических расстройств и нейродегенеративных расстройств.
EA200601982A 2004-05-27 2005-05-17 Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов EA200601982A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals
PCT/IB2005/001554 WO2005115985A1 (en) 2004-05-27 2005-05-17 Aminopyridine derivatives as selective dopamine d3 agonists

Publications (1)

Publication Number Publication Date
EA200601982A1 true EA200601982A1 (ru) 2007-04-27

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601982A EA200601982A1 (ru) 2004-05-27 2005-05-17 Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов

Country Status (21)

Country Link
EP (1) EP1758862A1 (ru)
JP (1) JP4198183B2 (ru)
AP (1) AP2006003824A0 (ru)
AR (1) AR049548A1 (ru)
AU (1) AU2005247699A1 (ru)
BR (1) BRPI0511571A (ru)
CA (1) CA2567935C (ru)
EA (1) EA200601982A1 (ru)
EC (1) ECSP067029A (ru)
GT (1) GT200500125A (ru)
IL (1) IL179314A0 (ru)
MA (1) MA28607B1 (ru)
MX (1) MXPA06013786A (ru)
NL (1) NL1029139C2 (ru)
NO (1) NO20065326L (ru)
PA (1) PA8635101A1 (ru)
PE (1) PE20060366A1 (ru)
SV (1) SV2005002129A (ru)
TW (1) TW200609216A (ru)
UY (1) UY28925A1 (ru)
WO (1) WO2005115985A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
MX2011008583A (es) * 2009-02-13 2011-12-12 Bayer Pharma AG Pirimidinas fusionadas.
EP2558437B1 (en) * 2010-04-12 2015-08-05 Supernus Pharmaceuticals, Inc. Methods for producing viloxazine salts and novel polymorphs thereof
EP2726171B1 (en) 2011-06-30 2017-05-17 Donaldson Company, Inc. Air/oil separator assemblies
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
EA037520B1 (ru) 2016-07-20 2021-04-07 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
EP3953350A1 (en) * 2019-04-12 2022-02-16 The United States of America, as Represented by The Department of Health and Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
EP4061367A1 (en) 2019-11-22 2022-09-28 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
SI1572214T1 (sl) * 2002-12-10 2010-07-30 Pfizer Ltd Derivati morfolina za uporabo kot dopaminski agonisti pri zdravljenju med drugim spolne disfunkcije

Also Published As

Publication number Publication date
AU2005247699A1 (en) 2005-12-08
EP1758862A1 (en) 2007-03-07
CA2567935A1 (en) 2005-12-08
PA8635101A1 (es) 2006-05-16
GT200500125A (es) 2006-01-10
UY28925A1 (es) 2005-12-30
MXPA06013786A (es) 2007-01-25
PE20060366A1 (es) 2006-05-15
JP4198183B2 (ja) 2008-12-17
IL179314A0 (en) 2007-03-08
TW200609216A (en) 2006-03-16
NL1029139C2 (nl) 2006-06-19
MA28607B1 (fr) 2007-05-02
CA2567935C (en) 2009-10-27
AR049548A1 (es) 2006-08-16
BRPI0511571A (pt) 2008-01-02
JP2008500331A (ja) 2008-01-10
NO20065326L (no) 2006-12-19
ECSP067029A (es) 2006-12-29
NL1029139A1 (nl) 2005-11-30
SV2005002129A (es) 2005-12-13
AP2006003824A0 (en) 2006-12-31
WO2005115985A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
EA200601982A1 (ru) Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
CY1119057T1 (el) Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
PH12017501522B1 (en) Antibodies to tau and uses thereof
EP2349170C0 (en) FEMALE SEXUAL DYSFUNCTION TREATMENT DEVICE
CL2012003132A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo[e]azulenos, antagonistas del receptor de la vla; proceso de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual masculina o femenina, hipertension y cirrosis hepatica, entre otros.
CL2012002905A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
PE20142040A1 (es) Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos
UA116894C2 (uk) Похідні піразину як агоністи канабіноїдного рецептора 2
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
AR076617A1 (es) Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.
TW200607500A (en) New indazole and indolone derivatives and their use as pharmaceuticals
PE20160787A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
DOP2005000095A (es) Nuevos derivados de aminopiridina y su uso como farmacos
DOP2005000093A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
EA201391459A1 (ru) Режимы лечения
MX2012014968A (es) Dosis fija de una combinacion farmaceutica de tadalafilo y dapoxetina.
EA201792070A1 (ru) Средство для лечения дисфункции лобной доли
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
MA38791A1 (fr) Pièce de raccordement pour moteur
RU2014137640A (ru) Способ сегментного упрочнения внутренней поверхности втулки